T

alk about a study in contrasts.

On Tuesday, the Food and Drug Administration issued a warning about contrast agents used in MRI scans, over concerns they contain a potentially toxic metal that can be left in the brain tissue. But regulators elsewhere have been far tougher on the issue: Last week, the U.K. National Health Service suspended two agents over the same concerns. The European Medicines Agency, meanwhile, has suspended use of three agents. Last month, Japan also restricted usage of some agents.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • A study ‘in contrasts,’ indeed! There are those who see it as clearly ‘black and white’ rather than White Oaks ‘many shades of gray.’

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

X